avatrombopag, rilzabrutinib and covid-19 updates in itp
Published 3 years ago • 353 plays • Length 1:26Download video MP4
Download video MP3
Similar videos
-
0:52
rilzabrutinib: a novel promising btk inhibitor being explored in itp
-
2:38
the management of itp during and after the covid-19 pandemic
-
4:20
itp update: diagnosis, treatment & covid-19 vaccines
-
6:00
covid-19 and mpn updates
-
1:53
avatrombopag: a novel oral therapy for the treatment of itp
-
0:44
the impact of the covid-19 pandemic on hematology nursing
-
2:31
management of all patients during covid-19
-
2:52
insights into how covid-19 will continue to impact patients with hematological malignancies
-
4:58
overview of the toxicities associated with bispecific agents in multiple myeloma
-
1:15:51
thursday webinar - vaccine-induced immune thrombocytopenia and thrombosis (vitt)
-
48:05
covid-19 insights: hypercoagulability (clotting) - part 2 (coagulation cascade.)
-
2:15
how covid-19 has impacted patients with hematological malignancies
-
1:10
avatrombopag following switch from eltrombopag or romiplostim in patients with itp
-
1:28
covid-19 vaccination in patients with itp
-
1:07
how covid-19 has impacted clinical practice and treatment approaches in multiple myeloma
-
4:43
hematological malignancy amid covid-19
-
1:54
immunogenicity of a third covid-19 vaccine dose in hematology patients with prior covid-19
-
2:29
impact of the covid-19 pandemic on multiple myeloma treatment
-
7:28
covid-19: impact on treating and diagnosing all
-
3:17
thrombopoietin receptor agonists in itp: current status and future outlooks
-
1:46
avatrombopag in patients with early versus chronic immune thrombocytopenia
-
2:06
improving treatment access with off-the-shelf bispecific antibodies in multiple myeloma